Quick Answer
Moleculin Biotech, Inc. reported Research And Development Expense of $15.89 million for the year ending 2025.
- Moleculin Biotech, Inc. showed a decrease of -10.4% in Research And Development Expense from 2024 to 2025.
- This data is from Moleculin Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $38.4 thousand | Q1 2016: $15.0 thousand | Q2 2016: $105.0 thousand | Q3 2016: $497.0 thousand | Q1 2017: $683.0 thousand | Q2 2017: $515.0 thousand | Q3 2017: $1.06 million | Q1 2018: $1.24 million | Q2 2018: $4.23 million | Q3 2018: $1.33 million | Q1 2019: $2.93 million | Q2 2019: $2.10 million | Q3 2019: $2.79 million | Q1 2020: $3.21 million | Q2 2020: $3.33 million | Q3 2020: $4.44 million | Q1 2021: $4.11 million | Q2 2021: $3.04 million | Q3 2021: $4.10 million | Q1 2022: $4.62 million | Q2 2022: $4.20 million | Q3 2022: $5.97 million | Q1 2023: $5.69 million | Q2 2023: $3.89 million | Q3 2023: $3.28 million | Q1 2024: $4.25 million | Q2 2024: $4.09 million | Q3 2024: $4.93 million | Q1 2025: $3.44 million | Q2 2025: $3.60 million | Q3 2025: $3.74 million.
- Over the full 10 years of available data (2016 to 2025), Moleculin Biotech, Inc.'s Research And Development Expense has grown by 962.2%.
- Historical annual values: Fiscal year 2025: $15.89 million | Fiscal year 2024: $17.73 million | Fiscal year 2023: $19.49 million | Fiscal year 2022: $18.97 million | Fiscal year 2021: $14.42 million | Fiscal year 2020: $12.76 million | Fiscal year 2019: $11.01 million | Fiscal year 2018: $9.73 million | Fiscal year 2017: $4.55 million | Fiscal year 2016: $1.50 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: